Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001291806 | SCV001480427 | uncertain significance | Rafiq syndrome | 2020-04-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001291806 | SCV003299273 | uncertain significance | Rafiq syndrome | 2022-04-09 | criteria provided, single submitter | clinical testing | This variant, c.129_134del, results in the deletion of 2 amino acid(s) of the MAN1B1 protein (p.Pro44_Pro45del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs766871551, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with MAN1B1-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004035585 | SCV004901055 | uncertain significance | Inborn genetic diseases | 2021-05-24 | criteria provided, single submitter | clinical testing | The c.129_134delGCCGCC (p.P44_P45del) alteration is located in exon 1 (coding exon 1) of the MAN1B1 gene. This alteration consists of an in-frame deletion of 6 nucleotides between nucleotide positions c.129 and c.134, resulting in the deletion of 2 residues. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |